Exclusive Interview: Aligning mRNA Progress With Regulatory Streamlining Industry—Got This Email Yesterday
The feeding frenzy continues Inside Pharma!
This is the overview of an mRNA webinar I received by email
“In this exclusive Peer Exchange video interview, Chris Spivey, Director of Industry Relations and Strategic Partnerships, Pharmaceutical Technology and BioPharm International, talks with industry experts about various aspects of mRNA scientific and commercial progress as it intersects with compliance and regulatory streamlining, potentially as a “platform” pathway.
Functionally, there isn’t just one type of structural modality - be it self-amplifying RNA (saRNA) or circular RNA (circRNA), handling and manufacturing aspects vary significantly. As they also do in terms of quantities, potency profiles, or absorption, distribution, metabolism, and excretion (ADME) considerations, or when discussing a generalized vaccine versus personalized oncology vaccines, gene editing, chimeric antigen receptors (CAR-T), antibodies, or protein replacement therapies.
One of the areas where we’ll discuss is using mRNA in the development of person…